Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC fiscal 2009 request

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission requests $256.2 million for its fiscal 2009 budget, an increase of $12.3 million that would support 18 additional FTEs, including 10 to work on consumer protection issues, according to information prepared for President Bush's budget request issued Feb. 4. FTC says it will continue to investigate deceptive marketing of health products, particularly those making disease prevention or weight-loss claims. As an example of its enforcement work, FTC cited the January 2007 settlements reached following investigations of false or unsubstantiated claims by marketers of Xenadrine EFX,CortiSlim,TrimSpa and One-A-Day WeightSmart (1"The Tan Sheet" Jan. 8, 2007, p. 4). The commission says it will continue to focus on health care products, including dietary supplements, "focusing its law enforcement on violations that create the greatest risks to consumer health"...

You may also be interested in...



FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action

Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel